Scott Pegan

Dr. Scott Pegan

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in ACS Infectious Diseases
Verified
Journal Article
Closed access
BFBrendan T. Freitas
Brendan T. Freitas
IDIan A. Durie
Ian A. Durie
JMJackelyn Murray
Jackelyn Murray
JLJaron E. Longo
Jaron E. Longo
HMHolden C. Miller
Holden C. Miller
SPScott Pegan
Scott Pegan

1 October 2019 in Journal of Molecular Biology
Verified
Journal Article
Open access
JDJohn Dzimianski
John Dzimianski
FSFlorine Scholte
Florine Scholte
EBEric Bergeron
Eric Bergeron
SPScott Pegan
Scott Pegan
Interferon-stimulated gene product 15 (ISG15) is a key component of host responses to microbial infection. Despite having been known for four decades, grasping the functions and features of ISG15 has been a slow and elusive process. Substantial work over the past two decades has greatly enhanced this understanding, revealing the complex and variable nature of this protein. This has unveiled multiple mechanisms of action that are only now beginning to be understood. In addition, it has uncovered diversity not only between how ISG15 affects different pathogens but also between the function and structure of ISG15 itself between different host species. Here we review the complexity of ISG15 within the context of viral infection, focusing primarily on its antiviral function and the mechanisms viruses employ to thwart its effects. We highlight what is known regarding the impact of ISG15 sequence and structural diversity on these interactions and discuss the aspects presenting the next frontier toward elucidating a more complete picture of ISG15 function.

1 June 2017 in Journal of Molecular Biology
Verified
Journal Article
Closed access
CDCourtney M. Daczkowski
Courtney M. Daczkowski
JDJohn Dzimianski
John Dzimianski
JCJozlyn R. Clasman
Jozlyn R. Clasman
OGOctavia Goodwin
Octavia Goodwin
AMAndrew D. Mesecar
Andrew D. Mesecar
SPScott Pegan
Scott Pegan

31 May 2020 in Virus Research
Verified
Journal Article
Closed access
BFBrendan T. Freitas
Brendan T. Freitas
FSFlorine E.M. Scholte
Florine E.M. Scholte
EBEric Bergeron
Eric Bergeron
SPScott Pegan
Scott Pegan

21 November 2018 in Chemical Research in Toxicology
Verified
Journal Article
Open access
SBStephanie M. Bester
Stephanie M. Bester
MGMark A. Guelta
Mark A. Guelta
JCJonah Cheung
Jonah Cheung
MWMark D. Winemiller
Mark D. Winemiller
SBSu Y. Bae
Su Y. Bae
JHJude J. Height
Jude J. Height
Over 50 years ago, the toxicity of irreversible organophosphate inhibitors targeting human acetylcholinesterase (hAChE) were observed to be stereospecific. The therapeutic reversal of hAChE inhibition by reactivators has also been shown to depend on the stereochemistry of the inhibitor. To gain clarity on the mechanism of stereospecific inhibition, the X-ray crystallographic structures hAChE inhibited by a racemic mixture of VX (PR/S) and its enantiomers were obtained. Beyond identifying hAChE structural features that lend themselves to stereospecific inhibition, structures of the reactivator HI-6 bound to hAChEs inhibited by VX enantiomers of varying toxicity, or in its uninhibited state, were obtained. Comparison of hAChE in these pre-reactivation and post-reactivation states along with enzymatic data reveals the potential influence of unproductive reactivator poses on the efficacy of these types of therapeutics. The recognition of structural features related to hAChE’s stereospecificity towards VX shed light on the molecular influences of toxicity and their effect on reactivators. In addition to providing a better understanding of the innate issues with current reactivators, an avenue for improvement of reactivators is envisioned.

1 January 2019 in Emerging Microbes & Infections
Verified
Journal Article
Open access
FSFlorine Scholte
Florine Scholte
JSJessica Spengler
Jessica Spengler
SWStephen R Welch
Stephen R Welch
JHJessica R. Harmon
Jessica R. Harmon
JCJoAnn D. Coleman-McCray
JoAnn D. Coleman-McCray
CSChristina Spiropoulou
Christina Spiropoulou
(2019). Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. Emerging Microbes & Infections: Vol. 8, No. 1, pp. 575-578.